Skip to content
Peptigraph home

Semaglutide for Joint Pain: What the Evidence Shows

What human and animal studies show about Semaglutide for joint pain, how strong that evidence is, and what is still unproven.

Medically reviewed by Juan Pablo Frías, MD · · DisclosureGLP-1 agonistUpdated
Strongest evidence
Human RCT
Human studies
1
with an outcome for joint pain, in our evidence file (PubMed search, 2 Oct 2026)
Animal studies
None found
with an outcome for joint pain, in our evidence file (PubMed search, 2 Oct 2026)
Studies we summarised
1
with an outcome for joint pain

Evidence for joint pain

Each row is an outcome related to joint pain from a published study, strongest design first. Animal and cell results are labelled and are not human results. User reports are not counted as evidence here.

Semaglutide for joint pain: outcomes in published studies
OutcomeResultStudy typeSource
Knee osteoarthritis pain (WOMAC)Pain score changed by -41.7 points with semaglutide vs -27.5 with placebo at week 68.Human RCTn = 407The New England journal of medicine 2024, PMID 39476339

Semaglutide and joint pain are not in our PubMed count ledger yet; the rows above come from our evidence file (PubMed search, 2 Oct 2026). Grades follow our .

How strong is it?

Strongest evidence:Human RCT evidence, 4 of 4The New England journal of medicine 2024, PMID 39476339

A human randomized trial outweighs any number of animal studies. Animal and cell results show a mechanism worth testing, not that it works in people.

Rheumatoid arthritis versus knee osteoarthritis

MedlinePlus defines rheumatoid arthritis as an autoimmune form of arthritis causing joint pain, swelling and stiffness, which differs from the knee osteoarthritis that semaglutide was actually tested in.[2]

The same MedlinePlus page says RA is an autoimmune disease, a different condition from the knee osteoarthritis studied in the semaglutide trial.[2]

The joint trial that does exist: semaglutide in knee osteoarthritis

The knee trial enrolled 407 people with obesity and knee osteoarthritis, and their average pain score at the start was 70.9.[1]

By week 68 the pain score had improved by 41.7 points on semaglutide and 27.5 points on placebo, so both groups improved and the difference is the part attributable to the drug.[1]

Body weight fell 13.7% on semaglutide against 3.2% on placebo in that trial; because weight and pain both changed, the trial cannot say how much of the pain relief came from weight loss.[1]

A narrative review of injectable peptides in sports medicine calls semaglutide the only class with reproducible randomised evidence of symptom relief in knee osteoarthritis, and says cartilage structure was not shown to change.[3]

Safety in that population

Serious adverse events were similar between groups in the knee trial, but stopping because of side effects, mostly gastrointestinal, was more common on semaglutide.[1]

Other peptides people research for joint pain

All peptides for joint pain, compared

Common questions

Does Semaglutide help with joint pain?

The strongest study we summarise for joint pain is human rct evidence, across 1 study with an outcome for joint pain. A trial result is not an approval; see the legal status.

Is Semaglutide approved for joint pain?

Semaglutide is FDA approved (Ozempic, Wegovy, Rybelsus). Which conditions that approval covers is set by the label; use for anything else is off-label.

What is the best peptide for joint pain?

There is no single answer. Our joint pain overview compares each candidate by evidence grade and legal status rather than by popularity.

Can semaglutide help rheumatoid arthritis?

No trial of semaglutide in rheumatoid arthritis was found, so there is nothing to cite for it; the joint evidence is for knee osteoarthritis with obesity.[1]

Does semaglutide reduce knee pain?

In the knee trial pain scores improved more on semaglutide than on placebo among people with obesity and moderate-to-severe pain, with weight loss alongside.[1]

More on Semaglutide

Sources

  1. 1Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis.The New England journal of medicine · 2024PMID 39476339Accessed 2 Oct 2026
  2. 2Official web pageOfficial web page · web page
  3. 3Injectable Peptides in Sports Medicine: A Structured Narrative Review of Evidence, Safety, and Antidoping Implications.JBJS reviews · 2026PMID 42160466Accessed 11 Oct 2026

Found an error? Report a correction.